Article
A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2010
Evers Bastiaan, Schut Eva, van der Burg Eline, Braumuller Tanya M, Egan David A, Holstege Henne, Edser Pauline, Adams David J, Wade-Martins Richard, Bouwman Peter, Jonkers Jos
Abstract excerpt
PURPOSE: Hereditary breast cancer is partly explained by germline mutations in BRCA1 and BRCA2. Although patients carry heterozygous mutations, their tumors have typically lost the remaining wild-type allele. Selectively targeting BRCA deficiency may therefore constitute an important therapeutic approach. Clinical trials applying this principle are underway, but it is unknown whether the compounds tested are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.